Natera Acquires Reproductive Health Assets from Invitae
22 Gennaio 2024 - 1:00PM
Business Wire
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA
(cfDNA) testing, today announced that it has acquired from Invitae
(NYSE: NVTA), a leading medical genetics company, certain assets
relating to Invitae’s non-invasive prenatal screening and carrier
screening business.
Natera has made an upfront payment in the amount of $10 million
to Invitae. In addition, the transaction includes $42.5 million in
potential milestone payments including cash and litigation-related
credits.
Pursuant to the agreement, Invitae will transition its
non-invasive prenatal screening and carrier screening customers to
Natera.
“We are committed to providing excellent service, and we look
forward to the opportunity to support additional patients and
providers,” said Steve Chapman, chief executive officer of
Natera.
About Natera
Natera™ is a global leader in cell-free DNA testing, dedicated
to oncology, women’s health, and organ health. We aim to make
personalized genetic testing and diagnostics part of the standard
of care to protect health, and inform earlier, more targeted
interventions that help lead to longer, healthier lives. Natera’s
tests are validated by more than 180 peer-reviewed publications
that demonstrate high accuracy. Natera operates ISO 13485-certified
and CAP-accredited laboratories certified under the Clinical
Laboratory Improvement Amendments (CLIA) in Austin, Texas and San
Carlos, California. For more information, visit www.natera.com.
Forward-Looking Statements
All statements other than statements of historical facts
contained in this press release are forward-looking statements and
are not a representation that Natera’s plans, estimates, or
expectations will be achieved. These forward-looking statements
represent Natera’s expectations as of the date of this press
release, and Natera disclaims any obligation to update the
forward-looking statements. These forward-looking statements are
subject to known and unknown risks and uncertainties that may cause
actual results to differ materially, including with respect to our
expectations regarding acquisitions, dispositions and other
strategic transactions, which could disrupt our business, cause
dilution to our stockholders or reduce our financial resources, or
our expectations of the benefits of our tests and product offerings
to patients, providers and payers. Additional risks and
uncertainties are discussed in greater detail in "Risk Factors" in
Natera’s recent filings on Forms 10-K and 10-Q and in other filings
Natera makes with the SEC from time to time. These documents are
available at www.natera.com/investors and www.sec.gov.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240121559590/en/
Investor Relations: Mike Brophy, CFO, Natera, Inc.,
510-826-2350, investor@natera.com Media: Lesley Bogdanow, VP of
Corporate Communications, Natera, Inc., pr@natera.com
Grafico Azioni Natera (NASDAQ:NTRA)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Natera (NASDAQ:NTRA)
Storico
Da Giu 2023 a Giu 2024